Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Hum Immunol ; 83(2): 130-133, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1509823

ABSTRACT

The stimulation of AT1R (Angiotensin II Receptor Type 1) by Angiotensin II has, in addition to the effects on the renin-angiotensin system, also pro-inflammatory effects through stimulation of ADAM17 and subsequent production of INF-gamma and Interleukin-6. This pro-inflammatory action stimulate the cytokine storm that characterizes the most severe forms of SARS-CoV-2 infection. We studied the effect of AT1Rab on the AT1R on 74 subjects with SARS-CoV-2 infection with respiratory symptoms requiring hospitalization. We divided the patients into 2 groups: 34 with moderate and 40 with severe symptoms that required ICU admission. Hospitalized subjects showed a 50% reduction in the frequency of AT1Rab compared to healthy reference population. Of the ICU patients, 33/40 (82.5%) were AT1Rab negative and 16/33 of them (48.5%) died. All 7 patients positive for AT1Rab survived. These preliminary data seem to indicate a protective role played by AT1R autoantibodies on inflammatory activation in SARS-CoV-2 infection pathology.


Subject(s)
Autoantibodies/immunology , COVID-19/immunology , Receptor, Angiotensin, Type 1/immunology , Adult , Aged , Aged, 80 and over , Autoantigens/immunology , Female , Hospitalization , Humans , Italy , Male , Middle Aged , Retrospective Studies , SARS-CoV-2/immunology
2.
J Med Virol ; 93(10): 5886-5895, 2021 10.
Article in English | MEDLINE | ID: covidwho-1432423

ABSTRACT

The clinical evolution of coronavirus disease 2019 (COVID-19) is highly variable and hospitalized patients can rapidly develop conditions requiring oxygen support, intensive care unit (ICU) or high dependency unit (HDU) care. Early identification of high-risk patients is mandatory. We retrospectively collected the medical history, symptoms, radiological, and laboratory findings of COVID-19 patients hospitalized between February and April 2020. Laboratory data were collected at the first, last, and middle times of hospitalization. We used arterial oxygen partial pressure and fractional inspired oxygen ratio (P/F) to evaluate respiratory status. Outcomes considered were death and ICU/HDU admission. We used the χ2 or Fisher's exact test to examine differences between categorical variables. Continuous variables were analyzed using the Wilcoxon matched pairs signed-ranks test and Mann-Whitney test sample test. Of 71 patients admitted, 92% had interstitial pneumonia, and 17% an unfavorable outcome. Negative predictors were age, cerebrovascular disease, obesity, and chronic obstructive pulmonary disease. Baseline P/F was strongly associated with all outcomes. Markers linked to immunological dysregulation like elevated neutrophil-to-lymphocyte ratio exhibited prognostic significance over time. A validated prognostic score comprehensive of all these conditions for early staging and management of COVID-19 patients is urgently needed. Further studies are desirable to evaluate whether laboratory tests can target early treatment in high-risk patients.


Subject(s)
COVID-19/diagnosis , COVID-19/mortality , Adult , Aged , Aged, 80 and over , Female , Hospitalization , Humans , Intensive Care Units , Italy/epidemiology , Male , Middle Aged , Patient Outcome Assessment , Respiration, Artificial , Retrospective Studies , Risk Factors , SARS-CoV-2
3.
Am J Case Rep ; 21: e926921, 2020 Nov 21.
Article in English | MEDLINE | ID: covidwho-940353

ABSTRACT

BACKGROUND Since December 2019, an outbreak caused by a novel coronavirus infection (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) occurred in Wuhan, China, and it rapidly spread all over the world. The clinical spectrum of coronavirus disease 2019 (COVID-19) is wide, with acute respiratory distress syndrome (ARDS) occurring in 15% of patients affected, requiring high oxygen support. Currently, there is no clearly effective antiviral therapy. Steroids and immunomodulators are under investigation for potential activity. Little is known about middle and long-term sequelae on respiratory function. According to some authors, COVID-19 could cause pulmonary fibrosis. We report 3 cases of pulmonary fibrosis detected on follow-up computed tomography (CT) imaging in 3 female patients who recovered from COVID-19 pneumonia in Italy (L'Aquila, Abruzzo). CASE REPORT All patients were female and had no significant previous respiratory disease or history of smoke exposure, and none had received high-flow oxygen support during treatment of the disease. In all cases, late onset of mild dyspnea, slow and incomplete respiratory recovery, and early evidence of fibrous signs on chest CT scan were characteristic of the clinical course. CONCLUSIONS This report focuses on a possible scenario of long-term lung damage in COVID-19 pneumonia survivors. Limitations are lack of long-term follow-up and functional data in the very early phase. It is advantageous that all COVID-19 pneumonia patients undergo serial chest CT and spirometry long-term follow-up for at least 1 year to assess residual damage. This is particularly relevant in those with slow respiratory recovery and long hospitalization.


Subject(s)
COVID-19/diagnosis , Lung/diagnostic imaging , Pulmonary Fibrosis/diagnosis , SARS-CoV-2 , Tomography, X-Ray Computed/methods , Aged , Aged, 80 and over , COVID-19/complications , COVID-19/epidemiology , Female , Humans , Middle Aged , Pandemics , Pulmonary Fibrosis/complications , Radiography, Thoracic
4.
Transplant Proc ; 52(9): 2614-2619, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-624694

ABSTRACT

BACKGROUND: Coronavirus disease 2019 (COVID-19) is a new infectious disease that emerged in China in late 2019 and is now spreading around the world. Social distancing measures were needed to reduce transmission, and lockdown included restricted access to health care facilities. The impact of COVID-19 on transplant recipients is unknown, but considering their immunosuppression status and associated comorbidities, they should be considered a high-risk population. METHODS: A kidney transplant center in Central Italy implemented a strategy to maintain follow-up of kidney transplant recipients by phone and e-mail during lockdown. Telephone interviews were used to administer a clinical questionnaire to patients, and e-mail was used to receive the results of diagnostic tests conducted in outpatient settings. RESULTS: From March 17 to April 23, 2020, a total of 143 kidney transplant recipients were contacted. Twenty-eight patients needed in-hospital consultation for problems unrelated to COVID-19, 3 of whom needed hospitalization. Eleven patients were managed at home for mild urinary or respiratory diseases, and 1 was referred to the hematologist. We identified 2 suspected cases of COVID-19 infection, and the patients were referred to hospital care. Immunosuppressive therapy was modulated, and intravenous corticosteroids and potentially effective antiviral therapy were administered with a favorable outcome. CONCLUSIONS: In the context of a lockdown, such as that occurring in response to COVID-19, we suggest implementing remote surveillance programs in kidney transplant recipients with the help of any available technology and offering medical consulting and logistic support as needed.


Subject(s)
Aftercare/methods , Coronavirus Infections/prevention & control , Kidney Transplantation/adverse effects , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Postoperative Complications/prevention & control , Telemedicine/methods , Betacoronavirus , COVID-19 , Coronavirus Infections/immunology , Coronavirus Infections/virology , Female , Humans , Immunosuppression Therapy/adverse effects , Italy/epidemiology , Male , Middle Aged , Pneumonia, Viral/immunology , Pneumonia, Viral/virology , Postoperative Complications/immunology , Postoperative Complications/virology , Quarantine , Risk Factors , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL